An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA
About the study
An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of RemsimaTM in Patients with Rheumatoid Arthritis.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Adult patients
- Patients with active RA
- Patients (or legal guardian, if applicable) who are willing to give informed consent for long term follow-up including access to all medical records
EXCLUSION CRITERIA
Exclusion Criteria:
- Patients with a history of hypersensitivity to infliximab
- Patients with a current or past history of chronic infection
- Patients with moderate or severe heart failure (NYHA class III/IV).
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Rheumatoid Arthritis
Age (in years)
18+
Participants needed
950
Est. Completion Date
Jun 30, 2026
Treatment type
Observational [Patient Registry]
Sponsor
Celltrion
ClinicalTrials.gov identifier
NCT02557295
Study number
CT-P13 4.2
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?